22766-68-3

Basic information

• Product Name: 1-Azabicyclo[2.2.2]octane-4-carboxylic acid ethyl ester
• Synonyms: 1-Azabicyclo[2.2.2]octane-4-carboxylic acid ethyl ester;Quinuclidine-4-carboxylic acid ethyl ester;ethyl-1-azabicyclo[2.2.2]octane-4-carboxylate
• CAS NO: 22766-68-3
• Molecular Formula: C₁₀H₁₇NO₂
• Molecular Weight: 183.25
• Mol File: 22766-68-3.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 233.4±40.0 °C(Predicted)
• Appearance: /
• Density: 1.09±0.1 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 9.44±0.12(Predicted)
• CAS DataBase Reference: 1-Azabicyclo[2.2.2]octane-4-carboxylic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Azabicyclo[2.2.2]octane-4-carboxylic acid ethyl ester(22766-68-3)
• EPA Substance Registry System: 1-Azabicyclo[2.2.2]octane-4-carboxylic acid ethyl ester(22766-68-3)

Safety Data

• Hazardous Substances Data: 22766-68-3(Hazardous Substances Data)

Usage

Description

1-Azabicyclo[2.2.2]octane-4-carboxylic acid ethyl ester, also known as Ethyl 4-Quinuclidinecarboxylate, is a chemical compound with a unique bicyclic structure. It is characterized by its ester functional group and plays a significant role in the synthesis of various pharmaceutical compounds.

Uses

Used in Pharmaceutical Industry:
1-Azabicyclo[2.2.2]octane-4-carboxylic acid ethyl ester is used as a reactant for the synthesis of azoniabicyclooctanes, which are known as muscarinic acetylcholine receptor antagonists. These antagonists are crucial in the development of medications targeting various conditions, such as Alzheimer's disease, urinary incontinence, and overactive bladder.
In the synthesis process, Ethyl 4-Quinuclidinecarboxylate serves as a key building block, contributing to the formation of the azoniabicyclooctane structure. Its reactivity and structural properties make it an essential component in the creation of these therapeutic agents.

Upstream product

• 22766-67-2 1-azabicyclo[2.2.2]octane-4-carboxylic acid ethyl ester hydrochloride 
• 939900-20-6 C₁₀H₁₉NO₃ 
• 1126-09-6 4-carbethoxypiperidine 
• 142851-03-4 1-tert-butyl 4-ethyl piperidine-1,4-dicarboxylate 
• 1276088-72-2 ethyl-4-(2-chloroethyl)-piperidine-4-carboxylate hydrochloride 
• 869112-14-1 1-(2-chloroethyl)-4-piperidinecarboxylic acid ethyl ester 

Downstream Products

• 26608-58-2 4-hydroxymethylquinuclidine 
• 45651-41-0 4-Methyl-chinuclidin 
• 461648-39-5 α,α-diphenyl-1-azabicyclo[2.2.2]octane-4-methanol 
• 55022-91-8 quinuclidine-4-carbaldehyde 
• 869112-31-2 4-[hydroxy(diphenyl)methyl]-1-(2-hydroxyethyl)-1-azoniabicyclo[2.2.2]octane bromide 
• 22766-67-2 1-azabicyclo[2.2.2]octane-4-carboxylic acid ethyl ester hydrochloride 

Relevant articles and documents

A More Sustainable Process for Preparation of the Muscarinic Acetylcholine Antagonist Umeclidinium Bromide

A more sustainable process for the synthesis of the long-acting muscarinic acetylcholine antagonist umeclidinium bromide is described. Specifically, we report the synthesis of ethyl 1-(2-chloroethyl)-4-piperidinecarboxylate, a key intermediate in the prep

Method for synthesizing intermediate of high-purity Umeclidinium bromide

The invention discloses a method for synthesizing intermediates 1-(2-chloroethyl) piperidine-4-formate and quinuclidin-4-carboxylic ester of Umeclidinium bromide, and particularly discloses a method for synthesizing an intermediate 1-(2-chloroethyl) piperidine-4-formate and quinuclidin-4-carboxylic ester of Umeclidinium bromide. According to the method, crude products of the intermediates 1-(2-chloroethyl) piperidine-4-formate and quinuclidin-4-carboxylate are purified in a molecular distillation or reduced pressure distillation mode, and the high-purity medical intermediates are obtained. Thepurification cost can be effectively reduced through molecular distillation or vacuum distillation, the yield is improved, and the product purity can reach 99% or above. According to the present invention, with the synthesis method, the 1-(2-chloroethyl) piperidine-4-formate and the quinuclidin-4-carboxylate are prepared, the process route is short, the amplified production is easy, and the yieldis high. The method has the characteristics of novel process, high yield, low cost, high product purity and the like.

Halogen-Bonded Supramolecular Capsules in the Solid State, in Solution, and in the Gas Phase

Supramolecular capsules were assembled by neutral halogen bonding (XB) and studied in the solid state, in solution, and in the gas phase. The geometry of the highly organized capsules is shown by an X-ray crystal structure which features the assembly of t